Aflibercept, a New Way to Target Angiogenesis in the Second Line Treatment of Metastatic Colorectal Cancer (mCRC) (vol 11, pg 489, 2016)

被引：0
|
作者：
Scartozzi, Mario [1 ,2 ]
Vincent, Loic [3 ]
Chiron, Marielle [4 ]
Cascinu, Stefano [5 ,6 ]
机构：
[1] Univ Hosp, Med Oncol, BDuilio Casula SS 554,Km 4,500,Bivio Sestu, I-09042 Monserrato, CA, Italy
[2] Univ Cagliari, Pole Univ Hosp, BDuilio Casula SS 554,Km 4,500,Bivio Sestu, I-09042 Monserrato, CA, Italy
[3] Sanofi Oncol External Innovat, Vitry Sur Seine, France
[4] Sanofi Oncol Translat Med, Vitry Sur Seine, France
[5] Univ Hosp, Med Oncol, Modena, Italy
[6] Univ Modena & Reggio Emilia, Modena, Italy
来源：
TARGETED ONCOLOGY | 2017年 / 12卷 / 01期
关键词：
D O I：
10.1007/s11523-016-0473-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：123 / 123
页数：1
相关论文
共 50 条
  • [1] Aflibercept, a New Way to Target Angiogenesis in the Second Line Treatment of Metastatic Colorectal Cancer (mCRC)
    Mario Scartozzi
    Loic Vincent
    Marielle Chiron
    Stefano Cascinu
    [J]. Targeted Oncology, 2016, 11 : 489 - 500
  • [2] Aflibercept, a New Way to Target Angiogenesis in the Second Line Treatment of Metastatic Colorectal Cancer (mCRC)
    Scartozzi, Mario
    Vincent, Loic
    Chiron, Marielle
    Cascinu, Stefano
    [J]. TARGETED ONCOLOGY, 2016, 11 (04) : 489 - 500
  • [3] Erratum to: Aflibercept, a New Way to Target Angiogenesis in the Second Line Treatment of Metastatic Colorectal Cancer (mCRC)
    Mario Scartozzi
    Loic Vincent
    Marielle Chiron
    Stefano Cascinu
    [J]. Targeted Oncology, 2017, 12 : 123 - 123
  • [4] Aflibercept - a new Angiogenesis Inhibitor in the Treatment of metastatic colorectal cancer
    Scharf, J. -G.
    [J]. GASTROENTEROLOGE, 2013, 8 (05): : 445 - 447
  • [5] Experience with Aflibercept as a second line chemotherapy in metastatic colorectal cancer
    Gonzalez-Flores, E.
    Gonzalez-Astorga, B.
    Urena M, T. Delgado
    Conde, V.
    Sanchez-Toro, C.
    Legeren Alvarez, M.
    Villaescusa, A.
    Galvez Montosa, F.
    Garcia-Garcia, J.
    [J]. ANNALS OF ONCOLOGY, 2016, 27 : 41 - 42
  • [6] Bevacizumab in the treatment of metastatic colorectal cancer (mCRC) in second- and third-line settings
    Giantonio, Bruce J.
    [J]. SEMINARS IN ONCOLOGY, 2006, 33 (05) : S15 - S18
  • [7] Treatment of metastatic colorectal Cancer Aflibercept/FOLFIRI can be widely used in the second Therapy Line
    不详
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (06) : 358 - 358
  • [8] BUDGET IMPACT ANALYSIS OF AFLIBERCEPT IN YHE TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC) IN POLAND
    Kaczor, M. P.
    Pawlik, D.
    Wojcik, R.
    Glasek, M.
    Pieczonka, A.
    Kraska, A.
    Zelazowski, K.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A621 - A621
  • [9] Ziv-aflibercept: A novel angiogenesis inhibitor for the treatment of metastatic colorectal cancer
    Chung, Clement
    Pherwani, Nisha
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2013, 70 (21) : 1887 - 1896
  • [10] Treatment patterns and costs in second-line (2L) metastatic colorectal cancer (mCRC)
    Teitelbaum, April H.
    Evans, Dana
    Yu, Elaine
    Morlock, Robert
    Byfield, Stacey DaCosta
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
12345